Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.
If we average out the two most recent price targets this month, we come out with a potential gain of 337% and...
Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.
Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability
NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) --...
Meet Dennis Nguyen CEO of Start-Up Investor, the Society Pass (Symbol: SOPA)
See a Dazzling Presentation!
Society Pass (SOPA) has quickly acquired 8 companies since going public in late 2021,...
Institutional Analyst: Our #1 Internet Company, Society Pass (Nasdaq: SOPA), Holds Appeal for Both...
Press Release:
February 28, 2023 07:30 ET | Source: Society Pass Incorporated
New York,...
New Report: Society Pass (SOPA), Our #1 Internet Company Trading Under $5.00.
Our #1 Internet Company Trading Under $5.00, Society Pass Holds Appeal for Both Traders and Long-Term Investors.
Smart for Life (SMFL) Announces Launch of Greens First Protein Bars.
New Line of Protein Bars Specifically Formulated with the Greens First PRO Line, Provides a Nutrient Dense Meal Replacement with 54 Super...
Smart for Life (SMFL) Announces 59% Increase in Revenues, Year-Over-Year
New Report Coming, Sign up to our Newsletter for Priority Notification.
Absolutely banging numbers, we view Smart...
Smart for Life (SMFL) Reports, Headlines and More.
Smart For Life Corporate Investor Center
2022, 28-11. ($0.40) Smart for Life (SMFL) Announces...
Cosmos Health (COSM) and Smart for Life (SMFL) Execute Letter of Intent for Strategic...
LOI Calls for the Provision of SMFL Pan-European Access and COSM North American Access for Products and Services
MIAMI...
Smart For Life (SMFL) $0.37 Announces Initiation of Equity Analyst Coverage by Dawson James...
Initiates with “Buy” recommendation and $8 price target.
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Smart for Life,...
Latest article
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
